| Literature DB >> 31412107 |
Roberta De Mori1, Mariasavina Severino2, Maria Margherita Mancardi3, Danila Anello1, Silvia Tardivo1, Tommaso Biagini4, Valeria Capra5, Antonella Casella6, Cristina Cereda7, Brett R Copeland8, Stella Gagliardi7, Alessandra Gamucci3, Monia Ginevrino1,6, Barbara Illi9, Elisa Lorefice10, Damir Musaev8, Valentina Stanley8, Alessia Micalizzi11, Joseph G Gleeson8, Tommaso Mazza4, Andrea Rossi2, Enza Maria Valente1,6.
Abstract
Basal ganglia are subcortical grey nuclei that play essential roles in controlling voluntary movements, cognition and emotion. While basal ganglia dysfunction is observed in many neurodegenerative or metabolic disorders, congenital malformations are rare. In particular, dysplastic basal ganglia are part of the malformative spectrum of tubulinopathies and X-linked lissencephaly with abnormal genitalia, but neurodevelopmental syndromes characterized by basal ganglia agenesis are not known to date. We ascertained two unrelated children (both female) presenting with spastic tetraparesis, severe generalized dystonia and intellectual impairment, sharing a unique brain malformation characterized by agenesis of putamina and globi pallidi, dysgenesis of the caudate nuclei, olfactory bulbs hypoplasia, and anomaly of the diencephalic-mesencephalic junction with abnormal corticospinal tract course. Whole-exome sequencing identified two novel homozygous variants, c.26C>A; p.(S9*) and c.752A>G; p.(Q251R) in the GSX2 gene, a member of the family of homeobox transcription factors, which are key regulators of embryonic development. GSX2 is highly expressed in neural progenitors of the lateral and median ganglionic eminences, two protrusions of the ventral telencephalon from which the basal ganglia and olfactory tubercles originate, where it promotes neurogenesis while negatively regulating oligodendrogenesis. The truncating variant resulted in complete loss of protein expression, while the missense variant affected a highly conserved residue of the homeobox domain, was consistently predicted as pathogenic by bioinformatic tools, resulted in reduced protein expression and caused impaired structural stability of the homeobox domain and weaker interaction with DNA according to molecular dynamic simulations. Moreover, the nuclear localization of the mutant protein in transfected cells was significantly reduced compared to the wild-type protein. Expression studies on both patients' fibroblasts demonstrated reduced expression of GSX2 itself, likely due to altered transcriptional self-regulation, as well as significant expression changes of related genes such as ASCL1 and PAX6. Whole transcriptome analysis revealed a global deregulation in genes implicated in apoptosis and immunity, two broad pathways known to be involved in brain development. This is the first report of the clinical phenotype and molecular basis associated to basal ganglia agenesis in humans.Entities:
Keywords: GSX2; basal ganglia; diencephalic-mesencephalic junction; homeobox; lateral ganglionic eminence
Mesh:
Substances:
Year: 2019 PMID: 31412107 PMCID: PMC6776115 DOI: 10.1093/brain/awz247
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501
Figure 1Brain MRI showing basal ganglia agenesis in Coronal (A) and axial reformatted (B and C) 3D T1-weighted and axial T2-weighted (D and E) images of a control subject demonstrate the normal appearance of basal ganglia. Corresponding images performed in Patient NG4690 at 2.5 years of age (F–J) and Patient NG4687 at 10.5 years of age (K–O) reveal bilateral agenesis of the putamina and globi pallidi (black asterisks). The caudate nuclei are dysmorphic with enlarged head (small arrows) and small nodules of periventricular grey matter in the body and tail (empty arrows). Note the additional hypoplasia of the thalami (arrowheads).
Figure 2Brain MRI showing DMJ and corticospinal tracts abnormalities in patients with Axial reformatted 3D turbo field echo (TFE) T1-weighted image in a healthy control (A) and in Patients NG4690 and NG4687 (B and C). Both patients present abnormal contour of the midbrain with fusion of the hypothalamus and midbrain and bilateral oblique linear hypointense stripes (arrowheads). Sagittal fractional anisotropy colour directional maps fused with 3D/TFE T1-weighted images and with motor tractography in a healthy control (D) and in Patients NG4690 and NG4687 (E and F). Images from patients reveal abnormal dorsal course of the corticospinal tracts at the level of the pons (arrows).
Figure 3Molecular dynamics of wild-type and mutant GSX2. (A) Instantaneous root-mean-square deviation (RMSD) of all GSX2 heavy atoms. (B) Root-mean-square fluctuations (RMSF) of residue coordinates during simulations. (C) Distance between amino acids forming the binding site for DNA and the DNA itself. Wild-type and mutant GSX2 are coloured in black and red, respectively. (D) 3D structure of the homeobox domain of the GSX2 protein in complex with the DNA; location of GSX2Q251 and water bridge bonds (red dashed lines) with the DNA, which do not form in presence of the GSX2Q251R mutation.
Figure 4Intracellular localization of wild-type and mutant GSX2. (A) Immunofluorescence showing GSX2 intracellular localization. Transfected HeLa cells were stained with anti-GSX2 (red) and DAPI (blue). Wild-type GSX2 localizes predominantly in the nuclei (64 ± 4% of counted cells versus 27 ± 10% with predominant cytoplasmic localization), while mutant GSX2Q251R localizes both in the nuclei (56 ± 4%) and cytoplasm (42 ± 9%). (B) Nucleus-cytoplasm fractionation experiments and related densitometries of western blotting, with cytoplasmic wild-type protein set at 1, demonstrate that sublocalization is predominantly nuclear for the wild-type protein (12.0 ± 3.83) while, compared to the wild-type, the mutant protein shows increased cytoplasmic (2.12 ± 0.36) and reduced nuclear (9.02 ± 3.25) localization. Results are shown as mean ± standard error of three (A) or four (B) independent experiments. *P ≤ 0.05.
Figure 5Impact of mRNA levels of GSX2 and downstream genes ASCL1, PAX6, DLX1 and DLX2 in fibroblasts from patients and controls. GSX2 and ASCL1 levels are significantly reduced, while expression levels of PAX6, DLX1 and DLX2 are increased in mutated cells compared to control cells. Results are shown as mean ± standard error of at least three independent experiments; *P ≤ 0.05.
Figure 6Whole transcriptome analysis. (A) Heat map of log-normalized mRNA expression counts for GSX2 p.S9* (green) and p.Q251R (pink) versus controls (light blue), built using the top 60 differentially expressed mRNAs. The image shows a common deregulation between GSX2-mutated patients that clearly differ from healthy controls. (B) Common genes differentially expressed in both mutant cell lines share a very similar behaviour in terms of log2FC over controls. Black dots represent log2FC values in p.S9* (x-axis) and p.Q251R group (y-axis). Red solid line is the regression line, with a coefficient of determination R2 = 0.95. (C) Real time PCR of SOX4 and MAP2 genes, confirming a significant downregulation in patients’ fibroblasts. (D) String analysis of GSX2-related pathways showing the interaction among proteins encoded by core deregulated genes.